Successful use of ustekinumab therapy in refractory severe atopic dermatitis
نویسندگان
چکیده
AD: atopic dermatitis IL: interleukin Th: T helper cell INTRODUCTION Moderate-to-severe atopic dermatitis (AD) often requires systemic treatments with immunomodulatory drugs. Unfortunately, systemic agents currently used for AD have extensive side effects, and many patients experience suboptimal therapeutic responses. Additionally, many of these treatments, such as cyclosporine A, can only be used for a limited time because of potentially deleterious side effects. Novel targeted treatments are now moving into clinical trials for AD, including ustekinumab.
منابع مشابه
Oral Selenium in the treatment of refractory severe Atopic dermatitis: Report of 4 cases
Atopic dermatitis (AD) is a chronic, inflammatory and pruritic skin disease with a prevalence of 10-20%. Recent studies suggested the effect of selenium on immunoregulation in AD. In this study we report 4 cases of atopic dermatitis according to Hafniin and Rajka criteria. Serum selenium levels were increased and serum total IgE were decreased in all patients. These results show that selenium i...
متن کاملSevere Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
Received May 30, 2012, Revised July 11, 2012, Accepted for publication September 20, 2012 Corresponding author: Francesc Messeguer, Deparment of Dermatology, Instituto Valenciano de Oncología, Mateo Pueyo nr.6, 5 CP:46800, Xátiva-Valencia, Spain. Tel: 34-685-529-231, Fax: 34-961-114-342, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative Common...
متن کاملUstekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients.
Patients with atopic dermatitis (AD) often require systemic immunosuppressant treatment, but the use of these drugs is limited by their potential toxicity and/or an insufficient therapeutic response. Recently, Puya et al.1 published the case of a patient with severe AD successfully treated with ustekinumab. We present a retrospective descriptive study of patients with severe AD treated with ust...
متن کاملAtopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy.
Ustekinumab is a biological agent that is currently approved for the treatment of moderate to severe plaque psoriasis. It is a monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses. Recently, it has been suggested that ustekinumab could represent a potential treatment for atopic dermatitis (AD).1e3 However, i...
متن کاملAssociation of LL-37 and IL-31 serum levels with SCORing Atopic Dermatitis (SCORAD) score in atopic dermatitis patients
Background: Atopic dermatitis is a chronic, recurrent inflammation of the skin, accompanied by severe pruritus. Immune system dysregulation and skin barrier defects are associated with the abnormalities in atopic dermatitis. Myriad pieces of evidence have pointed to the major roles of LL-37 and interleukin-31 (IL31)in atopic dermatitis. The studies on atopic dermatitis are still limited i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2015